BioLynx's Series A Round

BioLynx raised a round of funding on April 10, 2018. Investors include Puhua Capital.

BioLynx (百凌生物) is an in-vitro diagnostic reagent, small molecule target, and antibody raw material supply platform. The company is dedicated to the development and application of various novel…

Articles about BioLynx's Series A Round: